Study of visual and anatomical outcomes of aflibercept in good visual acuity baseline of wet age-related macular degeneration
Phase of Trial: Phase IV
Latest Information Update: 05 Feb 2018
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 04 Feb 2018 Status changed from active, no longer recruiting to completed.
- 22 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by University Medical Information Network-Japan record.
- 06 Nov 2013 New trial record